Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings

4. november 2026 opdateret af: University of Southern Denmark

Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings. A Randomised Controlled Trial With a Qualitative Follow-up on Shared Decision-making in the Danish Mental Healthcare (the DAN-SHARE Study)

The DAN-SHARE study evaluates the use of DECISION HELPER™-based patient decision aids (PtDAs) in mental healthcare by exploring the impact of using a DECISION HELPER™ in-consult PtDA on patient involvement in decision-making. The study compares treatment consultations that use a PtDA with treatment consultations in which SDM is practiced without the use of a PtDA and hypothesises that the use of an in-consult PtDA will increase patient involvement in decision-making. Additionally, the study explores how patients and clinicians in mental healthcare understand and experience SDM and the use of the PtDA as part of the SDM practice in mental healthcare.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Shared decision-making (SDM) is a collaborative model for treatment decision-making and is widely regarded as a cornerstone of patient-centered care. In SDM, patients and healthcare professionals jointly review available treatment options and identify the solution that best aligns with the patient's preferences and values. Patient decision aids (PtDAS) that are designed to support SDM by presenting treatment options and helping patients formulate and communicate their preferences, are often a central component of SDM. However, little is known about how healthcare professionals and patients understand and experience the use of patient decision aids in their clinical encounters. In particular, there is a lack of knowledge on the use of patient decision aids within mental healthcare.

This study aims to evaluate the impact of Decision Helper™-based PtDAs, when used in mental healthcare. Decision Helper™-based PtDAS are PtDAS designed by using a generic template known as the DECISION HELPER™. They are mandatory to develop and use as part of the implementation of SDM across all hospitals in the Region of Southern Denmark. However, there is a lack of knowledge of whether these PtDAs enhance SDM practices in psychiatric treatment consultations and supports people using mental health services in achieving greater involvement in treament decision-making.

In the study, patients are randomised to either an intervention group or an active control group. In the intervention group, treatment consultations are conducted using the Decision Helper™-based PtDA, whereas consultations in the control group follow SDM practices without the use of the PtDA. Additionally, the study explores patients' and mental healthcare professionals understanding and experiences the PtDAs as part of their SDM practice.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

62

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • In treatment for a mental health disorder in one of the participating settings of the study

Exclusion Criteria:

  • Unable to understand Danish language
  • Unable to provide verbal and written informed consent
  • Diagnosed with cognitive impairment or dementia

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: SDM practice by using a Decision Helper-based PtDA

Patients assigned to the intervention group will be exposed to a Decision Helper™-based PtDA during consultations in which treatment decisions or related issues are addressed. The Decision Helper™-based PtDAS used in these consultations follows a five-step process based on the core principles of shared decision-making: (1) framing the situation and explaining the purpose of the consultation; (2) clarifying the patient's preferred level of information; (3) exploring what matters most to the patient in the decision-making process; (4) presenting the available treatment options, including their advantages and disadvantages; and (5) asking whether the patient is ready to make a decision regarding their preferred treatment option.

Patients assigned to the control group will not be exposed to the Decision Helper™-based PtDA during treatment consultations in which decisions are made. However, because all healthcare professionals in the participating settings have received training in SDM, the control group constitutes an active control condition, as patients will still be exposed to the general principles of SDM during decision-making consultations.

Aktiv komparator: SDM without the Decision Helper-based PtDA

Patients assigned to the intervention group will be exposed to a Decision Helper™-based PtDA during consultations in which treatment decisions or related issues are addressed. The Decision Helper™-based PtDAS used in these consultations follows a five-step process based on the core principles of shared decision-making: (1) framing the situation and explaining the purpose of the consultation; (2) clarifying the patient's preferred level of information; (3) exploring what matters most to the patient in the decision-making process; (4) presenting the available treatment options, including their advantages and disadvantages; and (5) asking whether the patient is ready to make a decision regarding their preferred treatment option.

Patients assigned to the control group will not be exposed to the Decision Helper™-based PtDA during treatment consultations in which decisions are made. However, because all healthcare professionals in the participating settings have received training in SDM, the control group constitutes an active control condition, as patients will still be exposed to the general principles of SDM during decision-making consultations.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Patient involvement in decision-making
Tidsramme: Throughout study completion, an average of 3 months.

Observed level of patient involvement in decision making according to the OPTION 12 scale.

OPTION 12 measures the level of patient involvement in decision-making by assessing recordings of treatment consultations on a 5-point Likert scale (0 to 4). Raw score rangs from 0 to 48 and is converted to a score ranging from 0 to 100. Higher scores indicate a higher level of patient involvement.

Throughout study completion, an average of 3 months.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Patient-perceived level of involvement in decision-making
Tidsramme: Patient-assessed within two weeks after the treatment consultation.

Patient-reported perceived involvement in decision-making, measured using the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The SDM-Q-9 assesses the extent to which patients perceive themselves as being involved in decision-making. Patients rate their level of agreement with each of the 9 statements on a 6-point Likert scale. Raw scores range from 0 to 45 and are converted to a standardized score ranging from 0 to 100.

Patient-assessed within two weeks after the treatment consultation.
Clinician-perceived level of involving the patient
Tidsramme: Clinician-assessed within two weeks after the treatment consultation.

Clinician-reported perceived level of patient involvement in decision-making, measured using the clinician version of the 9-item Shared Decision Making Questionnaire (SDM-Q-Doc). The SDM-Q-Doc assesses the extent to which clinicians perceive that they involve patients in the decision-making process. Clinicians evaluate each of the 9 items on a 6-point Likert scale. Raw scores range from 0 to 45 and are converted to scores ranging from 0 to 100. Higher scores indicate greater clinician-perceived involvement of patients in decision-making.

Clinician-assessed within two weeks after the treatment consultation.
Personal recovery
Tidsramme: Patient-assessed within two weeks after the treatment consultation.

Patient-reported measure of personal recovery, assessed using the Brief INSPIRE-O. The Brief INSPIRE-O is a 5-item self-rated measure of recovery, i.e., a patient-reported outcome measure (PROM), that assesses personal recovery from the patient's perspective.

Each of the five statements is rated by the patient on a 5-point Likert scale ranging from 0 to 4. Item scores are summed and multiplied by 5 to generate a total score ranging from 0 to 100. Higher scores indicate higher levels of patient-perceived personal recovery.

Patient-assessed within two weeks after the treatment consultation.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. april 2026

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

29. februar 2028

Datoer for studieregistrering

Først indsendt

1. maj 2026

Først indsendt, der opfyldte QC-kriterier

9. juni 2026

Først opslået (Faktiske)

10. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • DAN-SHARE

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .